Dihexa: the angiotensin-derived oligopeptide that drives synaptogenesis via HGF/MET — and its hard preclinical ceiling.
Dihexa (N-hexanoyl-Tyr-Ile-His-Pro-Phe-His-Leu) is a synthetic oligopeptide derived from angiotensin IV, developed at Washington State University by Joseph Harding and colleagues. It activates the hepatocyte growth factor (HGF) / MET receptor pathway, driving spinogenesis and synaptogenesis in hippocampal tissue. In aged rodent cognitive models, it has shown striking effects. The problem is that it has never advanced to human trials, making it one of the more interesting and simultaneously most uncertain compounds in the nootropic peptide category.
- Derived from angiotensin IV through a series of structure-activity relationship modifications by the Harding lab at WSU.
- Primary mechanism: allosteric potentiation of HGF binding to the MET receptor tyrosine kinase, driving hippocampal spinogenesis and synaptogenesis.
- Animal data: significant cognitive improvement in aged rat models (Morris water maze, novel object recognition) at low doses.
- Vendor claims sometimes frame it as "millions of times more potent than BDNF" — this is a misleading comparison that requires context.
- No human pharmacokinetic, safety, or efficacy data.
- MET receptor is also expressed in cancer cells — the oncogenic signaling risk deserves attention.
From angiotensin IV to a synaptogenic oligopeptide
Dihexa emerged from research into the angiotensin IV (AT4) / insulin-regulated aminopeptidase (IRAP) system and its cognitive effects. Early work showed that AT4 fragments improved memory in rodents, but AT4 itself is peptidase-sensitive and blood-brain-barrier-impermeable. The Harding laboratory performed systematic structure-activity optimization to produce a modified peptide (the hexanoic acid N-terminal cap, combined with specific residue modifications) with improved proteolytic stability and CNS penetration.
Critically, the mechanism turned out to not involve IRAP directly. Subsequent work identified the HGF/MET axis as the primary pharmacological target. Dihexa acts as an allosteric potentiator — it enhances HGF binding to the MET receptor without itself being a direct agonist of MET. The amplified HGF/MET signal then drives the downstream cascade responsible for neurotrophin-like effects: dendritic spine formation (spinogenesis) and new synapse formation (synaptogenesis) in the hippocampus.
The HGF/MET mechanism in neuroplasticity
HGF (hepatocyte growth factor) is a pleiotropic growth factor that, despite its name, acts throughout the body including the CNS. In neural tissue, HGF/MET signaling promotes:
- Dendritic spine formation and stabilization — the structural correlate of synaptic strengthening
- Axonal growth and guidance during development and after injury
- Neuronal survival under stress conditions
- BDNF-like effects on synaptic plasticity pathways (though via distinct mechanisms)
The "millions of times more potent than BDNF" framing circulated in vendor literature derives from a comparison in a specific in vitro assay where dihexa induced spinogenesis at concentrations far lower than BDNF required to produce comparable effects in the same assay. This is a real experimental finding but an extraordinarily misleading claim in context: potency in one specific in vitro assay is not a general statement about comparative neurotrophin efficacy. BDNF has a completely different mechanism and receptor system (TrkB). The comparison is apples-to-oranges.
The rodent cognitive evidence
The primary published evidence for dihexa comes from the Harding laboratory at Washington State University:
- McCoy et al. (2013) — the foundational paper — showed that dihexa administered to aged rats significantly improved Morris water maze performance (spatial learning and memory) to levels comparable to young rats. Hippocampal spine density increased measurably (PMID: 23988340).
- Peripheral (subcutaneous) administration was effective — important because it suggests blood-brain barrier penetration, though the mechanism of CNS entry has not been fully characterized.
- Effects were dose-dependent, with an apparent therapeutic window; higher doses did not always produce greater effects.
- The specific cognitive domain studied (hippocampus-dependent spatial memory) is relevant to aging and Alzheimer's disease research.
The honest limitation: essentially all published dihexa research traces back to the Harding group or its direct collaborators. Independent replication at other institutions is very limited. The preclinical evidence, while striking in character, comes from a narrow research base.
The oncogenic MET signaling caveat
The MET receptor tyrosine kinase is a well-characterized proto-oncogene. MET amplification, overexpression, and activating mutations are driver events in multiple cancers including lung, gastric, and renal cell carcinoma. Pharmaceutical companies have invested heavily in MET inhibitors (capmatinib, tepotinib) as anticancer agents.
A compound that potentiates HGF/MET signaling is therefore activating a pathway with known oncogenic potential. The Harding lab's papers acknowledge this and argue that the dose levels and tissue-distribution profile of dihexa produce CNS-localized effects without systemic MET activation sufficient to drive oncogenesis. This argument may be correct. But it is a theoretical argument based on rodent pharmacokinetics — without human safety trials, the oncogenic risk profile in humans cannot be assessed.